First selective aldosterone-blocker now approved for CHF
Clinicians will soon be able to offer their patients the first aldosterone-receptor blocker to be approved for the treatment of congestive heart failure (CHF). The FDA recently approved eplerenone (Inspra, Pfizer) to improve the survival of stable patients with left ventricular systolic dysfunction and clinical evidence of CHF following an acute myocardial infarction (MI).
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Related Content
